The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.
Robert Fox, MD, FAAN
Advertisement
Articles by Robert Fox, MD, FAAN
Advertisement
Latest Updated Articles
AAN 2025: Tolebrutinib Shows Promise in Slowing Disability Progression for Secondary Progressive Multiple SclerosisPublished: April 9th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Long COVID May Elevate Risk of Cardiovascular Disease
2
Higher-Dose Semaglutide Achieves Significant Weight Reduction in Adults with Obesity
3
The Average Health Insurance Premium Now Costs $27k Per Year for a Family
4
Advanced Wearable Accelerometer Shows Promise in Detecting Functional Capacity and Outcomes in Heart Failure Patients
5
